| Literature DB >> 28540294 |
Liang Xu1,2,3, Yuanjian Fang1,2,3, Xudan Shi4, Xianyi Chen1,2,3, Jun Yu1,2,3, Zeyu Sun1,2,3, Jianmin Zhang1,2,3, Jing Xu1,2,3.
Abstract
Background. The ideal management of SAH patients with negative initial DSA findings remains unresolved. Objective. (i) To present risk factors, clinical courses, and outcomes in different types of SAH patients with negative DSA findings; (ii) to explore the differences of basal vein between aSAH patients and NASAH patients; and (iii) to evaluate the value of repeated DSA for these patients. Methods. All SAH patients with negative initial DSA findings between 2013 and 2015 in our hospital were enrolled and were further categorized as perimesencephalic SAH (PMN-SAH) or nonperimesencephalic SAH (nPMN-SAH). Risk factors, clinical courses, outcomes, and the basal vein drainage patterns were compared. Results. A total of 137 patients were enrolled in the present study. The PMN-SAH group had better GOS and mRS values at 1-year follow-up. Moreover, the nPMN-SAH group had a higher rate of complications. The basal vein drainage pattern showed significant difference when comparing each of the NASAH subtypes with aSAH groups. There was a significant higher rate of a responsible aneurysm in nPMN-SAH group upon repeated DSA. Conclusions. SAH patients with negative initial DSA findings had benign clinical courses and outcomes. Repeated DSA studies are strongly advised for patients with the nPMN-SAH pattern.Entities:
Mesh:
Year: 2017 PMID: 28540294 PMCID: PMC5433417 DOI: 10.1155/2017/2486859
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Demographics of patients with nonaneurysmal subarachnoid hemorrhage.
| NASAH | PMN-SAH | nPMN-SAH |
| |
|---|---|---|---|---|
| Sum (%) | 137 (100%) | 82 (59.9%) | 55 (40.1%) | NS |
| Male-female ratio | 76/61 (1.2/1) | 42/40 (1.05/1) | 33/22 (1.5/1) | 0.357 |
| Age (range) | 56.0 ± 10.4 (30–80) | 55.4 ± 9.6 (34–76) | 56.7 ± 13.7 (30–80) | 0.156 |
| Smoker (%) | 18 (13.1%) | 11 (13.4%) | 7 (12.7%) | 0.907 |
| Alcohol abusing (%) | 21 (15.3%) | 13 (15.9%) | 8 (14.5%) | 0.835 |
| Diabetes (%) | 7 (5.1%) | 3 (3.7%) | 4 (7.3%) | 0.438 |
| Hypertension (%) | 30 (21.9%) | 15 (18.3%) | 15 (27.3%) | 0.213 |
| Anticoagulant Using (%) | 4 (2.9%) | 2 (2.4%) | 2 (3.6%) | 1 |
NASAH: nonaneurysmal subarachnoid hemorrhage, PMN-SAH: perimesencephalic nonaneurysmal subarachnoid hemorrhage, nPMN-SAH: nonperimesencephalic nonaneurysmal subarachnoid hemorrhage; NS means can not be analyzed.
The clinical characteristics of nonaneurysmal subarachnoid hemorrhage.
| All NASAH ( | PMN-SAH ( | nPMN-SAH ( |
| |
|---|---|---|---|---|
| LOS, mean (range) | 8.5 ± 8.5 (2–75) | 7.7 ± 4.0 (2–16) | 12.9 ± 11.9 (2–75) | 0.001 |
| GCS | ||||
| Mild (13–15) | 132 (97.0%) | 82 (100%) | 50 (90.9%) | 0.009 |
| Middle (9–12) | 1 (0.7%) | 0 | 1 (1.8%) | |
| Severe (3–8) | 4 (2.3%) | 0 | 4 (7.3%) | |
| H-H grade | ||||
| Good (I-II) | 132 (96.4%) | 81 (98.8%) | 51 (92.7%) | 0.157 |
| Poor (III-IV) | 5 (3.6%) | 1 (1.2%) | 4 (7.3%) | |
| mFS | ||||
| 0-1 | 78 (56.9%) | 70 (85.4%) | 8 (14.5%) | <0.001 |
| 2–4 | 59 (43.1%) | 12 (14.6%) | 47 (85.5%) | |
| Complication | ||||
| Hydrocephalus | 14 (10.2%) | 3 (3.7%) | 11 (20.0%) | 0.001 |
| Cerebral vasospasm | 7 (5.1%) | 1 (1.2%) | 6 (10.9%) | 0.017 |
| Rebleeding | 1 (0.7%) | 0 | 1 (1.8%) | 0.401 |
| Pulmonary infections | 3 (2.2%) | 1 (1.2%) | 2 (3.6%) | 0.564 |
NASAH: nonaneurysmal subarachnoid hemorrhage, PMN-SAH: perimesencephalic nonaneurysmal subarachnoid hemorrhage, nPMN-SAH: nonperimesencephalic nonaneurysmal subarachnoid hemorrhage, GCS: Glasgow coma scale, H-H grade: Hunt-Hess grade, mFS: modified Fisher Scale; LOS: length of hospital stay.
Clinical characteristics of hydrocephalus patients in NASAH group.
| No hydrocephalus ( | Hydrocephalus ( |
| |
|---|---|---|---|
| Demography | |||
| Age | 56.4 ± 10.0 | 52.9 ± 13.3 | 0.147 |
| Gender (female) | 57 (46.3%) | 4 (28.6) | 0.205 |
| Smoker | 16 (13.0%) | 2 (14.3%) | 0.893 |
| Alcohol abuse | 18 (14.6%) | 3 (21.4%) | 0.504 |
| Hypertension | 26 (21.1%) | 4 (28.6%) | 0.524 |
| Diabetes | 5 (4.1%) | 2 (14.3%) | 0.100 |
| Clinical grade | |||
| GCS < 13 | 0 (0%) | 4 (28.6%) | <0.001 |
| Modified Fisher Scale > 1 | 56 (45.5%) | 11 (78.6%) | <0.001 |
| Bleed Pattern | |||
| PMN-SAH | 79 (63.4%) | 3 (21.4%) | 0.002 |
| nPMN-SAH | 44 (35.8%) | 11 (78.6%) | |
| Anterior circulationa | 96 (78.0%) | 12 (85.7%) | 0.506 |
| Posterior circulationb | 27 (21.9%) | 2 (14.3%) | |
| Intraventricular hemorrhage | 8 (6.5%) | 10 (71.4%) | <0.001 |
| Cortical hemorrhage | 22 (17.9%) | 3 (21.4%) | 0.745 |
EVD: external ventricular drain, GCS: Glasgow coma scale.
aAnterior circulation was characterized by blood mainly locating at anterior of the brain.
bPosterior circulation was characterized by blood mainly locating at posterior of the brain.
The prognosis of patient after charged from hospital.
| All NASAH ( | PMN-SAH ( | nPMN-SAH ( |
| |
|---|---|---|---|---|
| mRS at 3 months | ||||
| 0-1 | 96 (82.8%) | 66 (94.3%) | 30 (65.2%) | <0.001 |
| 2-3 | 17 (14.7%) | 4 (5.7%) | 13 (28.2%) | |
| 4–6 | 3 (2.5%) | 0 | 3 (6.6%) | |
| GOS at 3 months | ||||
| 5 | 110 (94.8%) | 70 (100%) | 40 (87.0%) | 0.003 |
| 4 | 3 (3.1%) | 0 | 3 (6.5%) | |
| 1–3 | 3 (3.1%) | 0 | 3 (6.5%) | |
| mRS at 1 year | ||||
| 0-1 | 78 (86.7%) | 46 (95.8%) | 32 (76.2%) | 0.006 |
| 2-3 | 10 (11.1%) | 2 (4.2%) | 8 (19.0%) | |
| 4–6 | 2 (2.2%) | 0 | 2 (4.8%) | |
| GOS at 1 year | ||||
| 5 | 87 (96.7%) | 48 (100%) | 39 (92.8%) | 0.09 |
| 4 | 1 (1.1%) | 0 | 1 (2.4%) | |
| 1–3 | 2 (2.2%) | 0 | 2 (4.8%) |
NASAH: nonaneurysmal subarachnoid hemorrhage; PMN-SAH: perimesencephalic nonaneurysmal subarachnoid hemorrhage; nPMN-SAH: nonperimesencephalic nonaneurysmal subarachnoid hemorrhage; GOS: Glasgow outcome scale, mRS: modified Rankin Scale.
21 patients (12 perimesencephalic and 9 nonperimesencephalic patients) were lost to follow-up after discharge.
Type of BVR in nonaneurysmal subarachnoid hemorrhage and aneurysmal subarachnoid hemorrhage patients.
| BVR type | PMN-SAH | nPMN-SAH | aSAH |
|
|
|
|---|---|---|---|---|---|---|
| Unilateral |
|
|
| 0.003 | 0.021 | 0.950 |
|
| ||||||
| A | 61 (38.1%) | 39 (39.0%) | 147 (55.3%) | |||
| B | 48 (30.0%) | 31 (31.0%) | 61 (22.9%) | |||
| C | 51 (31.9%) | 30 (30.0%) | 58 (22.8%) | |||
|
| ||||||
| Bilateral |
|
|
| 0.028 | 0.066 | 0.882 |
|
| ||||||
| AA | 15 (18.8%) | 9 (18.0%) | 50 (37.6%) | |||
| AB, BB | 26 (32.5%) | 16 (32.0%) | 38 (28.6%) | |||
| AC, BC | 26 (32.5%) | 19 (38.0%) | 32 (24.1%) | |||
| CC | 13 (16.2%) | 6 (12.0%) | 13 (9.8%) | |||
BVR: basal vein of Rosenthal; PMN-SAH: perimesencephalic nonaneurysmal subarachnoid hemorrhage; nPMN-SAH: nonperimesencephalic nonaneurysmal subarachnoid hemorrhage.
p1: statistical analysis was proceeded between PMN-SAH and aSAH group.
p2: statistical analysis was proceeded nPMN-SAH and aSAH group.
p3: statistical analysis was proceeded PMN-SAH and nPMN-SAH group.
Type of BVR in nonaneurysmal subarachnoid hemorrhage and aneurysmal subarachnoid hemorrhage patients.
| Author/year | Unilateral BVR type | Bilateral BVR type | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMN-SAH (%) | aSAH (%) | PMN-SAH (%) | aSAH (%) | |||||||||||
| A | B | C | A | B | C | AA | AB | AC | CC | AA | AB | AC | CC | |
| Watanabe et al. [ | 3 (25) | 2 (17) | 7 (58) | 79 (41) | 70 (37) | 42 (22) | 0 | NS | NS | NS | 22 (22) | NS | NS | NS |
| Alén et al. [ | 36 (24) | 66 (44) | 47 (32) | 116 (59) | 51 (26) | 31 (15) | 12 (13) | 41 (45) | 38 (42) | 54 (48) | 34 (30) | 24 (21) | ||
| van der Schaaf et al. [ | 21 (19) | 48 (43) | 21 (37) | 49 (58) | 26 (31) | 9 (11) | 4 (7) | NS | NS | 29 (53) | 15 (36) | NS | NS | 8 (19) |
| Yamakawa et al. [ | 10 (29) | 7 (20) | 18 (51) | 111 (57) | 61 (31) | 23 (12) | 2 (11) | NS | NS | NS | 32 (29) | NS | NS | NS |
| Daenekindt et al. [ | 49 (42) | 34 (30) | 32 (28) | 50 (46) | 31 (29) | 27 (25) | 13 (22) | 18 (31) | 28 (47) | 10 (17) | 28 (47) | 21 (36) | ||
| Song et al. [ | NS | NS | NS | NS | NS | NS | 10 (31) | 8 (25) | 8 (25) | 6 (19) | 34 (60) | 12 (21) | 9 (16) | 2 (4) |
| Kawamura et al. [ | 6 (32) | 8 (42) | 5 (26) | 33 (49) | 27 (35) | 7 (10.4) | 0 | 5 (50) | 3 (30) | 1 (10) | 14 (42) | 12 (36) | 7 (21) | |
| Sabatino et al. [ | 36 (46) | 31 (39) | 12 (15) | 50 (66) | 8 (11) | 18 (24) | NS | NS | NS | NS | NS | NS | NS | NS |
| Buyukkaya et al. [ | NS | NS | NS | NS | NS | NS | 14 (35) | 3 (9) | 12 (34) | 6 (17%) | 26 (74) | 5 (14) | 3 (9) | 1 (3) |
PMN-SAH: perimesencephalic nonaneurysmal subarachnoid hemorrhage; aSAH: aneurysmal subarachnoid hemorrhage; NS means no data was recorded. The idiopathic subarachnoid hemorrhage has not been described in detail; no group was divided.
Diagnostic yield of a repeated DSA investigation.
| Author/year | Study type | PMN-SAH | Positive | Misdiagnose rate | nPMN-SAH | Positive | Misdiagnose rate |
|---|---|---|---|---|---|---|---|
| Topcuoglu et al. [ | Retrospective | 31 | 0 | 0 | 36 | 3 | 8.3% |
| Jung et al. [ | Retrospective | 65 | 1 | 1.5% | 37 | 17 | 45.9% |
| Huttner et al. [ | Prospective | 38 | 0 | 0 | NS | NS | NS |
| Little et al. [ | Retrospective | 23 | 1 | 4.3% | 59 | 5 | 8.5% |
| Gupta et al. [ | Retrospective | 18 | 0 | 0 | 43 | 2 | 4.7% |
| Carvi y Nievas and Archavlis [ | Retrospective | 8 | 0 | 0 | 3 | 1 | 33.3% |
| Agid et al. [ | Retrospective | 28 | 0 | 0 | 28 | 4 | 14.3% |
| Fontanella et al. [ | Retrospective | 23 | 0 | 0 | 72 | 9 | 12.5% |
| Maslehaty et al. [ | Retrospective | 34 | 1 | 2.9% | 120 | 13 | 10.8% |
| Kelliny et al. [ | Retrospective | 35 | 0 | 0 | 37 | 6 | 16.2% |
| Delgado Almandoz et al. [ | Prospective | 29 | 1 | 3.4% | 39 | 2 | 5.1% |
| Lin et al. [ | Retrospective | 27 | 0 | 0 | 41 | 2 | 4.9% |
| DW et al. [ | Retrospective | 6 | 0 | 0 | 12 | 2 | 16.7% |
| Present study | Retrospective | 31 | 0 | 0 | 29 | 4 | 13.8% |
| Total | 365 | 4 | 1.1% | 556 | 70 | 12.6% | |
PMN-SAH: perimesencephalic nonaneurysmal subarachnoid hemorrhage; nPMN-SAH: nonperimesencephalic nonaneurysmal subarachnoid hemorrhage; NS means no data was recorded.